CAS: 29868-97-1; 11-(2-(4-Methylpiperazin-1-yl)Acetyl)-5,11-Dihydro-6H-Benzo[e]Pyrido[3,2-B][1,4]Diazepin-6-One Dihydrochloride
该化合物是一种合成化合物,主要被归类为抗氨基制剂,这意味着它有选择性地抑制了肌肉受体的乙酰胆碱作用,这一特性使得它有助于通过减少气态酸分泌来治疗各种胃肠紊乱,特别是胃溃疡.该物质通常以白色为白,以非白色晶状粉的形式呈现,在水中溶解,呈现出一种一般为中性的pH范围.其化学结构包括一个环,有助于其药理特性.
- 英文名称11-(2-(4-Methylpiperazin-1-yl)Acetyl)-5,11-Dihydro-6H-Benzo[e]Pyrido[3,2-B][1,4]Diazepin-6-One Dihydrochloride
- 中文名称盐酸哌仑西平
- IUPAC名称11-(2-(4-methylpiperazin-1-yl)acetyl)-5,11-dihydro-6H-benzo[e]pyrido[3,2-b][1,4]diazepin-6-one dihydrochloride
- 其它别名5,11-Dihydro-11-[(4-methylpiperazin-1-yl)acetyl]-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one dihydr°Chloride
- CAS编号29868-97-1
- MFCD编号:MFCD00055214
- EINECS号:249-907-5
- FDA UNII编号:10YM403FLS
- 分子式:C19H23Cl2N5O2分子量:424.33
- 产品CID: 1280718
- 同类组份化合物CAS28797-61-7 (free base)29868-97-1 (2HCl)84827-28-1 (hydrate)93173-05-8 (HCl)
- 产品分类原料药 → 消化系统用药 → 抑制胃酸分泌药
物理性质
MSDS等安全信息
合成工艺路线路线简述
海关参考信息
- 2912110000-甲醛
2912120000-乙醛
2912210000-苯甲醛
2921211000-乙二胺 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:EP-1639157-B1
优先权日:2003-06-27
标 题:Method of synthesising a crystalline material and material thus obtained
发明人：PRIBAT DIDIER
权利人:CENTRE NAT RECH SCIENT
摘要:The invention provides a method of synthesizing a crystalline material in which seeds ( 6 ) are produced of a catalyst that is adapted to dissolve carbon on a substrate ( 2 ) of a first material; carbon nanotubes ( 6 ) are grown from the seeds ( 6 ); and a layer is produced of a second material comprising at least one monocrystalline region ( 12 ) orientated from a seed ( 6 ). The invention also provides the material obtained by said method. Application to the synthesis of polycrystalline silicon on a glass substrate.
专利号:US-11612610-B2
优先权日:2018-12-14
标题:Mito-magnolol compounds and methods of synthesis and use thereof
发明人：KALYANARAMAN BALARAMAN; ZIELONKA JACEK MICHAL; CHENG GANG; HARDY MICAEL JOËL; OUARI OLIVIER
权利人:MEDICAL COLLEGE WISCONSIN INC; AIX MARSEILLE UNIV; MEDICAL COLLEGE OF WISCONSIN INC
摘要:The present invention provides mito-magnolol compounds, pharmaceutical compositions thereof, and methods of using the mito-magnolol compounds in the treatment of cancer, especially anti-cancer therapy or kinase resistant cancers.
专利号:US-11897910-B2
优先权日:2015-06-11
标 题:Mito-honokiol compounds and methods of synthesis and use thereof
发明人：KALYANARAMAN BALARAMAN; ZIELONKA JACEK MICHAL; CHENG GANG; HARDY MICAEL J; OUARI OLIVIER; YOU MING
权利人:MEDICAL COLLEGE WISCONSIN INC; AIX MARSEILLE UNIV
摘要:The present invention provides mito-honokiol or mito-magnolol compounds, pharmaceutical compositions thereof, and methods of using the mito-honokiol or mito-magnolol compounds in the treatment of cancer.
专利号:EP-2920193-A1
优先权日:2012-11-16
标 题:Synthesis of carbohydrate-based surfactants
专利号:EP-0831366-A1
优先权日:1996-09-24
标 题 :Synthesis of matte beads containing a carboxylic acid monomer and their use in photographic elements
专利号:WO-2014077960-A1
优先权日:2012-11-16
标题 :Synthesis of carbohydrate-based surfactants
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Del Tacca M, Danesi R, Blandizzi C, Bernardini MC. Un antimuscarinico selettivo: la pirenzepina. Rassegna delle sue proprietà farmacologiche e cliniche [A selective antimuscarinic agent: pirenzepine. Review of its pharmacologic and clinical properties]. Minerva Dietol Gastroenterol. 1989 Jul- Sep;35(3):175-89. Italian. 11(1):23397. doi: 10.1038/s41598-021-02732-y.
3: Davis MP, Dickerson ED. Olanzapine: another psychotropic? Am J Hosp Palliat Care. 2001 Mar-Apr;18(2):129-32. doi: 10.1177/104990910101800212. Erratum in: Am J Hosp Palliat Care 2001 Jul-Aug;18(4):274. 58(9):442-5. 32(2):275-6. doi: 10.1016/s0196-0644(98)70162-3. Erratum in: Ann Emerg Med 1998 Nov;32(5):637. 43(6):1252-3. 350(9077):594. doi: 10.1016/S0140-6736(05)63186-8. 15(5):351-6. 37(1):149-50. doi: 10.1345/aph.1C288. 158(7):1158. doi: 10.1176/appi.ajp.158.7.1158. 19(2):192. doi: 10.1097/00004714-199904000-00022. 35(2):51-3. 56(4):400-1. doi: 10.1046/j.1365-2044.2001.01976-50.x. 37(12):1243-4. doi: 10.1097/00004583-199812000-00004. 354(9178):566-7. doi: 10.1016/S0140-6736(99)03111-6. 42(4):370. doi: 10.1176/appi.psy.42.4.370. 156(7):1118-9. doi: 10.1176/ajp.156.7.1118. 158(12):2087-8. doi: 10.1176/appi.ajp.158.12.2087-a. 41(2):150-1. doi: 10.1176/appi.psy.41.2.150. 36(4):563-4. doi: 10.1046/j.1440-1614.2002.t01-7-01066.x.
合成参考文献
摘要:Polish Journal of Pharmacology and Pharmacy., 33(615), 1981
摘要:Gekkan Yakuji. Pharmaceuticals Monthly., 23(1999), 1981
摘要:Oyo Yakuri. Pharmacometrics., 9(377), 1975
摘要:Iyakuhin Kenkyu. Study of Medical Supplies., 19(735), 1988
参考文献:10.1007/bf00498734
摘要:Court JA, Fowler CJ, Candy JM, Hoban PR, Smith CJ. Raising the ambient potassium ion concentration enhances carbachol stimulated phosphoinositide hydrolysis in rat brain hippocampal and cerebral cortical miniprisms. Naunyn Schmiedebergs Arch Pharmacol. 1986 Sep;334(1):10–6. doi: 10.1007/bf00498734.
📝 需求与反馈
尽可能描述清楚需求与问题信息
